By Delilah Alvarado
June 15, 2026
Johnson & Johnson (J&J) has marked a significant milestone in its oncology portfolio, announcing positive Phase 3 clinical trial results that showcase the efficacy of its bispecific antibody, Talvey (talquetamab), when used in combination with its blockbuster therapy, Darzalex Faspro (daratumumab and hyaluronidase-fihj). The findings, released on June 15, 2026, suggest a potential shift in the standard of care for multiple myeloma, aiming to move the treatment into earlier lines of therapy.
This development is critical for the pharmaceutical giant as it navigates a transitional period characterized by the loss of exclusivity for its flagship autoimmune drug, Stelara, and an aggressive push to solidify its dominance in the oncology sector.
The Core Data: A Shift in Treatment Paradigms
The primary takeaway from the latest study is the demonstration of superior progression-free survival (PFS) in patients treated with the combination therapy compared to current standard-of-care regimens. J&J reported that this is the first time a GPRC5D-directed bispecific antibody has shown such robust results in earlier-line settings for multiple myeloma.
Talvey, which received its initial FDA approval in 2023, was originally indicated for heavily pre-treated adult patients—those who had already cycled through at least four lines of therapy. By proving its efficacy in earlier stages of the disease, J&J is positioning Talvey to transition from a "last-resort" treatment to a foundational component of initial or secondary care.
The mechanism of action remains a key differentiator. Talvey is a bispecific T-cell engager (BiTE) that binds simultaneously to the CD3 receptor on T-cells and the GPRC5D protein, which is highly expressed on the surface of malignant plasma cells. By effectively bridging the patient’s own immune system to the cancerous cells, the drug triggers a potent immune-mediated destruction of the tumor.
Chronology: The Evolution of J&J’s Myeloma Portfolio
To understand the weight of today’s announcement, one must look at the strategic timeline of J&J’s oncology development:
- 2015: The FDA grants approval to Darzalex (daratumumab), which quickly becomes a cornerstone of multiple myeloma care due to its ability to target CD38-positive cells.
- 2020: The approval of Darzalex Faspro, the subcutaneous formulation, significantly improves patient convenience and reduces infusion time, cementing J&J’s market leadership.
- August 2023: The FDA grants accelerated approval for Talvey (talquetamab) for patients with relapsed or refractory multiple myeloma, targeting the GPRC5D protein.
- 2024–2025: J&J’s oncology division experiences substantial growth, reaching $25.4 billion in annual revenue in 2025—a 22% increase year-over-year.
- June 2026: J&J announces positive Phase 3 trial data, setting the stage for regulatory filings to expand Talvey’s label to earlier lines of treatment.
Supporting Data: Economic and Clinical Momentum
The clinical success of Talvey is mirrored by its commercial trajectory. In 2025, Talvey generated $463 million in revenue, representing a 61% surge from its first full year on the market ($287 million in 2024). While these figures are modest compared to the multi-billion-dollar status of Darzalex, the growth trajectory signals high physician adoption and strong demand for novel mechanisms in a crowded myeloma market.
The overall oncology business remains the engine of J&J’s pharmaceutical division. With total oncology revenues jumping from $20.8 billion in 2024 to $25.4 billion in 2025, the company has successfully demonstrated that its pivot toward high-growth cancer therapies is paying dividends.
The combination of Talvey and Darzalex Faspro is not merely a clinical experiment; it is a calculated commercial strategy. By bundling their proprietary assets, J&J is creating a "vertical" treatment ecosystem. If regulators approve the combination for earlier lines of therapy, J&J will essentially own a larger portion of the patient journey, from diagnosis through multiple stages of relapse.
The Strategic Imperative: Life After Stelara
The urgency behind J&J’s oncology push is inextricably linked to the "Stelara cliff." For years, the autoimmune blockbuster Stelara served as the company’s primary revenue driver. However, with the onset of biosimilar competition, J&J has had to rapidly diversify its income streams.
Investors have been closely monitoring how the company plans to offset the revenue decline. The success of its oncology portfolio—specifically drugs like Talvey, Carvykti, and the expanded use of Darzalex—has become the primary answer to these concerns. By moving Talvey into earlier treatment lines, J&J is not only extending the drug’s patent life and market relevance but also securing a stable, long-term revenue base that is less susceptible to the cyclical pressures faced by older drugs.
Implications for Patients and the Healthcare System
Clinical Implications
For patients, the move to earlier-line therapy is a potential game-changer. Multiple myeloma is a complex, often incurable malignancy that necessitates long-term management. Providing patients with a bispecific antibody combination earlier in their treatment cycle may lead to deeper, more durable remissions, potentially delaying the need for more toxic treatments or stem cell transplants.
Regulatory Implications
J&J has confirmed it is actively engaged with global regulatory authorities to discuss the submission of these Phase 3 results. The process will likely involve a rigorous review of safety data, particularly regarding cytokine release syndrome (CRS) and other immune-related side effects common to bispecific antibodies. If the FDA and the European Medicines Agency (EMA) accept the data, it could lead to a label expansion by early-to-mid 2027.
Competitive Landscape
This development places significant pressure on competitors like Bristol Myers Squibb and Pfizer, who are also racing to develop the next generation of myeloma treatments. By proving that a GPRC5D-targeting agent can work effectively alongside a CD38-targeting agent like Darzalex, J&J has set a high bar for efficacy. Future clinical trials in this space will now be measured against this combination, forcing rivals to demonstrate not just parity, but superiority.
Looking Ahead: The Future of J&J Oncology
The June 15 announcement represents a pivotal moment in J&J’s long-term corporate strategy. As the company continues to shed its legacy consumer health business and refine its pharmaceutical focus, the success of its oncology pipeline will determine its future valuation.
The next 12 to 18 months will be critical. Analysts will be watching for the specific timing of the supplemental Biologics License Application (sBLA) filing with the FDA and any additional data readouts that might further clarify the safety profile of the Talvey-Darzalex combination.
For now, the message from New Brunswick is clear: Johnson & Johnson is betting heavily on its ability to redefine the standard of care in blood cancers. With the clinical data to back its ambition and a proven commercial engine to drive adoption, the company appears well-positioned to maintain its leadership in the treatment of multiple myeloma for the foreseeable future.
As the oncology landscape evolves, the integration of targeted therapies like Talvey will remain a litmus test for the pharmaceutical industry’s ability to turn complex, high-science innovation into sustainable, patient-focused solutions.
About the Author
